NYSE Suspends Trading in Accendra Health Over “Abnormally Low” Stock Price
Key Facts
The New York Stock Exchange suspended trading in Accendra Health common stock and began delisting proceedings, saying the stock was no longer suitable for listing because its selling price had reached “abnormally low” levels under Section 802.01D of the Listed Company Manual. The exchange announced its decision in a statement, citing the price decline as the direct reason for the action. The suspension follows two separate notices the company received in October concerning continued-listing standards. The first notice concerned the average closing price, while the second addressed market capitalization and shareholders’ equity. The developments put the company’s earlier efforts to address its deficiencies to a new test as delisting proceedings begin and trading is suspended.
Accendra Health said in a quarterly filing that it received a notice from the New York Stock Exchange on October 6 stating that its average closing share price had remained below $1.00 for 30 consecutive trading sessions. The notice gave it six months from the date of receipt to regain compliance with that standard. As part of its remediation efforts, the company said it had called a special meeting of shareholders to approve a reverse stock split at a ratio ranging from 1-for-20 to 1-for-30. The proposal was intended to address the minimum-price violation, but was contingent on a shareholder vote. The company said in the filing that it could not guarantee approval or implementation of the proposal.
On October 27, the company received another notice concerning Section 802.01B of the Listed Company Manual. The New York Stock Exchange said Accendra Health had failed to meet the requirement that its average market capitalization be at least $50.0 million over 30 consecutive trading sessions, and the requirement that shareholders’ equity be at least $50.0 million. This notice was separate from the price notice issued about three weeks earlier. The company said at the time that the notice did not immediately affect the listing of its shares, provided it complied with the other continued-listing requirements. The market-capitalization and shareholders’ equity process allowed a separate period and compliance plan from the deadline for addressing the share price.
Under the October 27 notice, the company had 45 calendar days to submit a business plan explaining how it would regain compliance with the market-capitalization and shareholders’ equity standards within 18 months of the notice date. The company said the New York Stock Exchange would review the plan and, if it accepted it, the company would be subject to quarterly monitoring. This process differs from the six-month period the exchange gave it to address its average closing price. The company described the two frameworks in its filings as separate continued-listing requirements. But the delisting proceedings and trading suspension were announced by the exchange because of abnormally low selling-price levels, according to the NYSE.
In its quarterly filing on the price-related challenges, Accendra Health linked the possibility of continued trading below the minimum threshold to the loss of significant payer contracts and its exit from the healthcare products and services business. It said the decline in its share price and recent financial challenges could contribute to the stock remaining below the minimum-price requirement. The company recorded a loss from continuing operations, after tax, of $18.0 million in the third quarter of 2026, compared with a loss of $5.6 million in the third quarter of 2025. Chief Executive Kenny Gardner-Smith said the company’s results since the start of 2026 had been “well below our expectations and potential.” He added that a value-creation plan would be implemented over the coming months.
The company warned that delisting and subsequent over-the-counter trading could significantly reduce liquidity and make shares harder to sell, as well as weaken its ability to raise capital. These risks take on added importance in light of the trading suspension announced by the New York Stock Exchange, which could limit shareholders’ ability to trade the stock during the delisting proceedings. The company’s filings did not specify the outcome of the reverse-split vote or whether the compliance plan concerning market capitalization and shareholders’ equity had been accepted. Approval and implementation remained uncertain, the company said. The timeline it announced for addressing the market-capitalization standard calls for submitting the plan within 45 calendar days and quarterly monitoring if the exchange accepts it.